GlaxoSmithKline Pharmaceuticals Limited — Updates, 13-05-2025: Press Release

GlaxoSmithKline Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue rose 9% to Rs. 3,723 Cr, with Profit After Tax before exceptional items up 32% to Rs. 915 Cr, and EBITDA margins improving 500 bps to 31.4%. Q4 revenue grew 6% LFL to Rs. 966 Cr, with PAT at Rs. 260 Cr. Growth was driven by a diversified portfolio, strong brand performance, and digital acceleration. Oncology drug launches Zejula and Jemperli are planned for FY26 to boost growth.